Peter Zaffino

And it was a very tangible Y2K-style moment.

Exactly.

Where there was, let's just say, a powerful business strategy.

I think some people's reaction would be, are we not doing record keeping here already?

No, we're good.

So you can opt into this program by just saying that you're opting into it, but then even the reporting, once you're opted in, is voluntary.

Yeah, I mean, the news is just that there's incredible momentum in biotech.

It feels like it.

Early-stage biotech.

but it's notable because biotech had been uh left for dead in some ways we had a biotech investor on probably 14 months ago at this point who said i don't even know i mean just looking at the return so far i don't know why you would invest in this asset class yeah

But of course, every asset class kind of goes through that kind of phase.

And clearly, there's a lot of momentum.

Yeah, didn't we have a guy on that had sold?

Like three companies.

We didn't have Mondo.

He had $2 billion exits.

So anyways, you have Isomorphic Labs spun out of DeepMind.

Coinbase, or not Coinbase, but Brian spun out or like founded New Limit.

You have Retro Biosciences.

As well.